ReviewDrug design, development and therapy2019

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.

Smriti Subedi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.